Abstract: The disclosure belongs to the technical field of batteries, and particularly relates to a current collector component, which includes a first current collector piece, a second current collector piece, and an insulator, the first current collector piece and the second current collector piece being in insulated connection through an insulator; and the second current collector piece includes a body part, a welding part, and a connecting part, the body part being connected to the insulator and provided with a first electrical connection surface, the connecting part being connected between the body part and the welding part, and the connecting part being bendable, so that the welding part is located on the side, far away from the first electrical connection surface, of the body part. The structure of the disclosure may increase the utilization rate of the internal space of a housing.

Abstract: The disclosure belongs to the technical field of batteries, and particularly relates to a current collector component, which includes a first current collector piece, a second current collector piece, and an insulator, the first current collector piece and the second current collector piece being in insulated connection through an insulator; the second current collector piece includes a body part and a welding part, the body part and the welding part forming an included angle, and a welding surface of the welding part and a surface of the body part forming an included angle. The structure of the disclosure has high welding safety, may increase the utilization rate of the internal space of a housing, and may prevent the damage to a cell caused by laser penetration welding. In addition, the disclosure further discloses a secondary battery.

Abstract: The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.

Abstract: Provided is an isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human CD40. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same are further provided.

Abstract: The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.

Abstract: Provided is an ST2 antigen binding protein, such as a mouse, human, chimeric or humanized antibody or antigen binding fragment thereof that specifically binds to ST2. Also provided are nucleic acid molecules encoding the above-mentioned antibodies and antigen binding fragments thereof, and an expression vector and host cell for expressing the antibodies or antigen binding fragments thereof. Further provided are methods for preparing and using the antibodies and antigen binding fragments thereof. The methods comprise treating and preventing IL33/ST2-mediated related diseases or conditions.

Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

Abstract: An isolated monoclonal antibody that specifically binds human IL4R?, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. The present disclosure further provides a bispecific molecule, an oncolytic virus and a pharmaceutical composition comprising the antibody or the antigen-binding portion thereof, as well as a treatment method using an Anti-IL4R? antibody or the antigen-binding portion thereof of the disclosure.

Abstract: A quinoline derivative for treating rheumatoid arthritis and a use thereof in preparing a pharmaceutical composition for treating rheumatoid arthritis. In particular, a use of the quinoline derivative 1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropanamine in treating rheumatoid arthritis.

Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

Abstract: A bogie and a rail vehicle, wherein the bogie includes: a framework, a wheel pair connected to the framework, a braking hanger fixed to the framework, a hanger slider used for fixedly connecting to a vehicle wheel braking clamp, and a transmission member; the hanger slider is connected to the braking hanger, and the transmission member is connected to the hanger slider; a first end of the transmission member extends to a side surface of a vehicle wheel in the wheel pair, and the transmission member is used to drive the hanger slider to move along the lateral direction with respect to the braking hanger when the first end is subjected to a thrust applied in the lateral direction by the vehicle wheel, so that the vehicle wheel braking clamp moves to a position corresponding to the vehicle wheel.

Abstract: Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).

Abstract: A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Abstract: The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.

Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.

Abstract: Disclosed is an isolated monoclonal antibody that specifically binds human TSLP, or the antigen-binding portion thereof. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present disclosure further provides a bispecific molecule, an immunoconjugate, a CAR-immune cell, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-TSLP antibody of the disclosure.

Abstract: Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.

Abstract: Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a ROR? inhibitor, said compound has good ROR? inhibitory activity and is expected to be used for treating diseases mediated by a ROR? receptor in mammals.

Abstract: Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.

Abstract: Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the medical uses thereof in treating diseases benefiting from the capsid protein assembly inhibitor, particularly diseases caused by hepatitis B virus infection.